Supplement evidence

022 / 575Fatty acid

Omega-3 fatty acids

View my plan →

The short answer

Prescription-strength products lower very high triglycerides; selected cardiovascular uses are population- and formulation-specific.

Evidence and scope: Conditional or population-specific
This status does not grade the ingredient for every goal, outcome, or person.
Important limitation: Ordinary fish-oil supplements are not proven life-extension products for healthy adults.
Before deciding: High doses may increase atrial-fibrillation or bleeding concerns and can interact with medicines.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective

Meeting usual needsCommon food/supplement target: 250–500 mg/day EPA+DHA

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

High triglycerides4 g/day prescription omega-3 under clinical care

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityFat-soluble / lipid-based

Fat-soluble or lipid-based. Absorption generally improves with a meal containing fat.

How it is commonly taken

Take with a fat-containing meal; split doses for reflux.

Do not combine casually

Anticoagulants, atrial-fibrillation history, and surgery warrant review; prescription products are not equivalent to fish-oil capsules.

Dose and use source ↗

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

4research papers in this ledger

4unique primary studies represented

48,155unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2021

Does not support the tested claimPMID 33191772 · NCT01841944

Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction

The trial did not detect a reduction in clinical events.

Published: 2021Duration: 2 yearsn=1,027 participants

Study design and methods

Design: Randomized, controlled trial
Population: Adults aged 70–82 after a recent myocardial infarction
Intervention: EPA/DHA 1.8 g/day versus corn oil
Outcome: Composite cardiovascular events

Open research record ↗

2020

Does not support the tested claimPMID 33190147 · NCT02104817

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events

The trial was stopped early for futility and did not demonstrate cardiovascular benefit.

Published: 2020n=13,078 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled trial
Population: Statin-treated adults at high cardiovascular risk with dyslipidemia
Intervention: EPA/DHA carboxylic acids 4 g/day versus corn oil
Outcome: Major adverse cardiovascular events

Study period: 2014–2020

Open research record ↗

2019

Does not support the tested claimPMID 30415637 · NCT01169259

Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer

The supplement did not reduce either primary endpoint in the overall cohort.

Published: 2019Duration: Median 5.3 yearsn=25,871 participants

Study design and methods

Design: Randomized, placebo-controlled trial
Population: Generally healthy U.S. adults at usual cardiovascular risk
Intervention: Marine omega-3 fatty acids 1 g/day versus placebo
Outcome: Major cardiovascular events and invasive cancer

Open research record ↗

2019

Supports a specific usePMID 30415628 · NCT01492361

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Icosapent ethyl reduced ischemic events in this specific high-risk population, with more atrial-fibrillation hospitalizations and a numerical increase in serious bleeding.

Published: 2019Duration: Median 4.9 yearsn=8,179 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled trial
Population: Statin-treated, high-risk adults with elevated triglycerides
Intervention: Prescription icosapent ethyl 4 g/day versus mineral-oil placebo
Outcome: Major ischemic events

Funding or conflict note: Funded by Amarin Pharma.

Open research record ↗

Unscreened discovery appendix—not evidence6,050 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

Official evidence overviewNIH Office of Dietary Supplements Live PubMed discovery searchNational Library of Medicine

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

Public endorsement

Andrew Huberman

Neuroscientist and health educator

Encourages reaching 1–3 g/day of EPA from food or supplements for mood and brain-function goals. This does not endorse fish oil for lifespan or general cardiovascular prevention.

Source date: 2022
Context / disclosure: The episode mentions a supplement affiliate. Expert opinion is displayed separately from trial evidence.

Huberman Lab — Focus Toolkit ↗

Personal use

Rhonda Patrick

Biomedical scientist and health educator

Describes a personal DHA regimen using dietary and supplemental omega-3 sources. Personal use is not presented as a population-wide recommendation.

Source date: 2020-08-13
Context / disclosure: Personal practice and education content; not counted as scientific evidence.

FoundMyFitness — Omega-3 phospholipid DHA and supplementation ↗